Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2023 | Buy → Neutral | H.C. Wainwright | |
| 3/7/2022 | $5.00 | Buy | Lake Street |
| 11/23/2021 | $6.00 | Buy | HC Wainwright & Co. |
New telehealth offering empowers consumers to use pre-tax healthcare funds at FSA Store® and HSA Store® to make heart health a part of everyday life with at-homemonitoring DALLAS and REDWOOD CITY, Calif., Sept. 9, 2025 /PRNewswire/ -- Health-E Commerce®, the parent brand to FSA Store® and HSA Store®, today announced a new collaboration with Biotricity® (OTCQB:BTCY), an innovative medical technology company offering clinically reliable solutions for consumers and healthcare professionals. Through this arrangement, Biotricity's continuous 24/7 wearable cardiac monitoring solution, Bioheart®, will now be available to more than 70 million consumers who are enrolled in FSAs and HSAs.
REDWOOD CITY, Calif./BELFAST, Northern Ireland, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative medical technology company specializing in remote cardiac monitoring solutions, and B-Secur, a leader in ECG algorithm and biosensing technology, are transforming the consumer wearables market with an enhancement to their joint cardiac monitoring platform. The device-neutral platform, which launched in early 2025 for ambulatory cardiac monitoring, will now support ECG data from consumer wearables. This advancement enables the seamless integration and review of user data collected from smartwatches, smart rings, fitness trackers, and other mobile health products wi
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, e
10-Q - BIOTRICITY INC. (0001630113) (Filer)
10-K - BIOTRICITY INC. (0001630113) (Filer)
NT 10-K - BIOTRICITY INC. (0001630113) (Filer)
H.C. Wainwright downgraded Biotricity from Buy to Neutral
Lake Street initiated coverage of Biotricity with a rating of Buy and set a new price target of $5.00
HC Wainwright & Co. initiated coverage of Biotricity with a rating of Buy and set a new price target of $6.00
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
4 - BIOTRICITY INC. (0001630113) (Issuer)
SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)
SC 13G - BIOTRICITY INC. (0001630113) (Subject)
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, e
Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14, 2025 at 4:30PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Sid
FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni